—

Halozyme Therapeutics Inc (HALO) — the peer cohort

As of 2026-09-25 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Halozyme Therapeutics Inc ranks 1 of 7 in its cohort on the Closelooknet composite (74/100) — the highest reading in the cohort.

NameCompositeMomentumQualityValuationSignalOff 52w high
HALO Halozyme Therapeutics Inc 74 95 94 46 ok 2.5%
BION.SW BB Biotech AG 73 66 96 81 info 10.4%
ARGX.BR Argen-X 64 74 74 29 ok 8.6%
ARGX argenx NV ADR 64 74 73 29 ok 10.6%
ONC BeiGene, Ltd. 64 79 62 32 ok 6.3%
KRYS Krystal Biotech Inc 61 68 85 19 ok 9.6%
PTGX Protagonist Therapeutics Inc 60 82 60 11 info 11.8%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-09-25

Quick answers

Who are Halozyme Therapeutics Inc's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: BB Biotech AG (BION.SW), Argen-X (ARGX.BR), argenx NV ADR (ARGX), BeiGene, Ltd. (ONC), Krystal Biotech Inc (KRYS), Protagonist Therapeutics Inc (PTGX).

How does HALO score against its peers?

Halozyme Therapeutics Inc's composite reads 74/100, ranking 1 of 7 in its cohort as of 2026-09-25 — the highest in the cohort. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.